Topic: cell manufacturing
Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.
Lonza CEO Marc Funk is leaving for "personal reasons" after less than a year in the top job.
Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.
Just weeks after selling its share in Brammer Bio in a $1.7 billion deal, Ampersand has an agreement to buy another CDMO with viral vector expertise.
In a transcontinental move, a California biotech working on a cell therapy for solid tumors will build its first manufacturing site in Philadelphia.
With FDA approval of Zolgensma expected soon, Novartis CEO Vasant Narasimhan is confident that the company's manufacturing network will meet demand.
The FDA has issued guidance on continuous manufacturing and is allocating $58 million to move forward advanced manufacturing processes.
General Electric is selling its biomanufacturing operations to conglomerate Danaher for $21.4 billion.
Novartis biotech AveXis will invest another $60 million and hire another 200 workers for the site it is building in Durham, North Carolina.
Japan’s Hitachi has acquired European cell manufacturing CDMO with two facilities in Germany.